Bli medlem
Bli medlem

Du är här


Karolinska Development AB (publ): Vesalius Biocapital III Partners invests in Karolinska Development's portfolio company Fo...

STOCKHOLM, September 5, 2018. Karolinska Development's portfolio company
Forendo Pharma announces today that Vesalius Biocapital III Partners
(Vesalius) joins Forendo Pharma's existing international investor syndicate.
Forendo Pharma has raised funding of EUR 4 million from Vesalius. Stéphane
Verdood, Managing Partner from Vesalius, joins Forendo Pharma's Board of

Vesalius Biocapital III Partners invests in later stage European life science
companies in drug development, medtech, diagnostics and eHealth / mHealth,
and is a fund managed by Vesalius Biocapital Partners, a specialist life
sciences venture capital investor.

The funding enables Forendo Pharma to accelerate development of its innovative
women's health portfolio. Forendo Pharma's lead program FOR 6219 in
development for treatment of endometriosis, has commenced a Phase Ia study
focusing on the general safety, tolerability and pharmacokinetics. The first
women participating in the study have been dosed. Forendo Pharma's second
program, a dual HSD Inhibitor for the treatment of broader gynecological
conditions, is currently in preclinical discovery stage.

Endometriosis, a chronic condition that affects up to 10 per cent of women in
reproductive age, causes repeated pain symptoms, infertility and impaired
quality of life. Currently available treatments for endometriosis have
limitations in efficacy or cause harmful side effects, due to estrogen

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB

Phone: +46 73 982 52 02, e-mail:


About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make
a difference to patients' lives while providing an attractive return on
investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes
in the Nordic region. The Company aims to build companies around scientists
who are leaders in their fields, supported by experienced management teams
and advisers, and co-funded by specialist international investors, to provide
the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with
a proven track record as company builders and with access to a strong global

For more information, please

KD Press release Forendo September 2018

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.